Lisa McKerracher, PhD: Founder and Chief Executive Officer

Dr. Lisa McKerracher is a successful entrepreneur and business executive. She is the Founder and CEO of BioAxone BioSciences, and is a serial entrepreneur with extensive experience in company start-up, preclinical research and clinical development. Dr. McKerracher created BioAxone in 2011, after acquiring all rights to a Phase II biologic drug to treat spinal cord injury. In 2013, BioAxone BioSciences was selected as one of 10 Life Sciences to participate in the prestigious Springboard program for women entrepreneurs leading high growth companies. BioAxone’s lead program was also selected by Elsevier Business Intelligence and Windhover Conferences as a “Top 10 Neurosciences Program to Watch.” Dr. McKerracher is past CEO of Emerillon Therapeutic, a genomics company, VP at ReGen Nautic, a clean-tech company, and CSO at her first spin-out company. Dr. McKerracher is a recognized leader in regenerative medicine and translational neuroscience, and was a co-recipient of the Christopher Reeve Research Medal for Spinal Cord Repair in 2000 with Dr. Albert Aguayo. She has 15 years of experience in academic research and left a tenured position to pursue her passion for drug development. Dr. McKerracher has published more than 60 research articles in leading journals and has edited a book on spinal cord injury. She has over 30 issued patents as Inventor. Currently, Dr. McKerracher is an Adjunct Professor at McGill University, and Scientific Officer for the Canadian Institute of Health Research Proof-of-Principal commercialization grant committee. She is also a member of a National Institute of Neurological Disorders and Stroke (NINDS)/SBIR review committee for the NIH. Dr. McKerracher holds a BSc from McGill University and PhD from York University, and received post-doctoral training at the Worcester Foundation for Experimental Biology (Massachusetts) and McGill University.

 

Kenneth Rosen, PhD: Vice President  of Research

Dr. Ken Rosen is an accomplished neuroscientist who brings 25 years of molecular neuroscience experience to BioAxone. Dr. Rosen has an extensive background in studying the biology of trophic molecules, the regulation of neurotransmitter receptors, and in translating discoveries to preclinical models of neurological disease. At BioAxone, Dr. Rosen leads the preclinical research program and is responsible for the identification of potential targets in our regenerative medicine discovery program.  After earning his BS in Biology from Boston College and his PhD in Molecular Biology from Vanderbilt University, he trained as a post-doctoral fellow with Dr. Lydia Villa-Komaroff at Boston Children’s Hospital defining the role of insulin-like growth factors during both nervous system and skeletal muscle development. After completing his training, he was the senior scientist in Dr. Gerald Fischbach’s laboratory at Massachusetts General Hospital and Harvard Medical School, where he was the first to identify and clone neuregulin-1, a trophic factor not only of critical importance for the nervous system, but also a component of a key signaling pathway in oncology. Following these discoveries, he became a member of the faculty at Tufts Medical School, where he studied the pathobiology of degenerative disorders of the nervous system, including Alzheimer’s disease and Parkinson’s disease. He later returned to Boston Children’s Hospital to study trophic factor signaling in myelination and in nerve responses to injury before leaving academia to join Takeda Pharmaceuticals. At Takeda, Dr. Rosen gained experience in the GxP environment (GLP and GMP) and developed assays to understand how different production processes impact biological equivalence.

 

Lisa Bond, PhD: Senior Director of Clinical and Regulatory Affairs

MeDr. Lisa Bond manages clinical and regulatory development at BioAxone. She has a strong science background focused on the downstream cytoskeletal portion of the Rho signaling pathway, as well as hands-on experience with neurotrauma rehabilitation. Dr. Bond is passionate about the selection of endpoints for spinal cord injury clinical trials that reflect meaningful improvements in daily function. She spoke recently on this topic at the National Neurotrauma Society Symposium and has written a review on cervical spinal cord injury endpoints with Dr. McKerracher for Neural Regeneration Research. Dr. Bond graduated summa cum laude from the University of North Carolina at Chapel Hill with a BS in Biology and a minor in Chemistry. She earned a PhD in Clinical Biochemistry at the University of Cambridge as both a Churchill Scholar and a National Institutes of Health-Oxford-Cambridge Scholar. Dr. Bond has held postdoctoral positions at the National Heart, Lung and Blood Institute and the Medical Research Council Laboratory of Molecular Biology.

 

Pierre Caouette

Pierre Caouette-small

Mr. Caouette is Chief Operating Officer and of the Board of BioAxone BioSciences. He is a serial entrepreneur who has expertise in leading company strategy in various industries that include biotechnology, clean technology and high technology.  Mr. Caouette’s background is in computer science, mechanical / electrical engineering and aviation. He holds a valid ATPL (Airline Transport Pilot License), having been captain for the 8th largest airline, where his computer and mechanical engineering skilled were called upon at a management level. Mr. Caouette was an early entrant to computer technology, and founded Hexadecimal Canada Inc. (Hexacan) in 1984. Some of Hexacan routines are still in use today in Microsoft’s Operating Systems. Hexacan was sold to a public company in 1990. After the sale of his company, Mr. Caouette, continued to work as a consultant in the field. In 2000, Mr. Caouette co-Founded BioAxone Therapeutic (Canada) and lead investor. During his tenure as CEO, Mr. Caouette raised over $15M in financing, grew the company to 35 employees, and oversaw cGMP drug manufacturing. These accomplishments resulted in the company receiving recognition as a “Top Ten Canadian Biotech Company” for three years in a row. He was member of the Canadian Olympic Sailing Team for 14 years. In 2005, after leaving BioAxone Canada, he sailed around the world on his own boat, before starting a clean technology company in the marine field. Some of the custom “world record type” electric propulsion systems that he developed are still in use today, and he continues to consult in the field. Since joining BioAxone as COO in 2015, BioAxone’s valuation has jumped 7-fold.